Details
Stereochemistry | ACHIRAL |
Molecular Formula | C25H30N3 |
Molecular Weight | 372.5258 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 1 |
SHOW SMILES / InChI
SMILES
CN(C)C1=CC=C(C=C1)C(C2=CC=C(C=C2)N(C)C)=C3C=CC(C=C3)=[N+](C)C
InChI
InChIKey=LGLFFNDHMLKUMI-UHFFFAOYSA-N
InChI=1S/C25H30N3/c1-26(2)22-13-7-19(8-14-22)25(20-9-15-23(16-10-20)27(3)4)21-11-17-24(18-12-21)28(5)6/h7-18H,1-6H3/q+1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/24118276 | http://www.webmd.com/drugs/2/drug-4397/gentian-violet-topical/detailsCurator's Comment: Description was created based on several sources, including https://www.drugbank.ca/drugs/DB00406
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24118276 | http://www.webmd.com/drugs/2/drug-4397/gentian-violet-topical/details
Curator's Comment: Description was created based on several sources, including https://www.drugbank.ca/drugs/DB00406
Gentian violet ((GV) hexamethyl pararosaniline, also known as crystal violet, methyl violet) is a triphenylmethane dye with anti-bacterial, anti-fungal, anti-helminithic, anti-trypanosomal, anti-angiogenic and anti-tumor properties. GV has a lengthy history and has been used successfully as monotherapy and an adjunct to treatment in a variety of diseases. Gentian violet interacts with negatively charged components of bacterial cells including the lipopolysaccharide (on the cell wall), the peptidoglycan and DNA. A similar cell penetration and DNA binding process is thought to take place for fungal cells as well. Because Gentian violet is a mutagen and mitotic poison, cell growth is consequently inhibited. A photodynamic action of gentian violet, apparently mediated by a free-radical mechanism, has recently been described in bacteria and in the protozoan T. cruzi. Evidence also suggests that gentian violet dissipates the bacterial (and mitochondrial) membrane potential by inducing permeability. This is followed by respiratory inhibition. This anti-mitochondrial activity might explain gentian violet's efficacy towards both bacteria and yeast with relatively mild effects on mammalian cells.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24118276
Curator's Comment: Synthesis of Gentian violet was attributed French chemist Charles Lauth in 1861 under the name of ‘Violet de Paris
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2366922 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18579783 |
22.13 nM [EC50] | ||
Target ID: CHEMBL2364041 |
|||
Target ID: CHEMBL368 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21478242 |
30.6 µM [IC50] | ||
Target ID: CHEMBL2364041 |
|||
Target ID: Thioredoxin reductase 2, fungal Sources: https://www.ncbi.nlm.nih.gov/pubmed/24118276 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | GENTIAN VIOLET Approved UseTopical gentian violet is used to treat some types of fungus infections inside the mouth (thrush) and of the skin. |
|||
Preventing | GENTIAN VIOLET Approved UseGentian violet has weak antibacterial effects and may be used on minor cuts and scrapes to prevent infection. |
Doses
Dose | Population | Adverse events |
---|---|---|
1 % single, ophthalmic |
unhealthy, 55 years n = 1 Health Status: unhealthy Age Group: 55 years Sex: F Population Size: 1 Sources: |
Other AEs: Keratoconjunctivitis... |
2 % 10 times / day multiple, oral Dose: 2 %, 10 times / day Route: oral Route: multiple Dose: 2 %, 10 times / day Sources: |
unhealthy, infant n = 1 Health Status: unhealthy Age Group: infant Population Size: 1 Sources: |
Disc. AE: Swollen tongue, Oral mucosa pain... AEs leading to discontinuation/dose reduction: Swollen tongue Sources: Oral mucosa pain |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Keratoconjunctivitis | 1 % single, ophthalmic |
unhealthy, 55 years n = 1 Health Status: unhealthy Age Group: 55 years Sex: F Population Size: 1 Sources: |
|
Oral mucosa pain | Disc. AE | 2 % 10 times / day multiple, oral Dose: 2 %, 10 times / day Route: oral Route: multiple Dose: 2 %, 10 times / day Sources: |
unhealthy, infant n = 1 Health Status: unhealthy Age Group: infant Population Size: 1 Sources: |
Swollen tongue | Disc. AE | 2 % 10 times / day multiple, oral Dose: 2 %, 10 times / day Route: oral Route: multiple Dose: 2 %, 10 times / day Sources: |
unhealthy, infant n = 1 Health Status: unhealthy Age Group: infant Population Size: 1 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes [Activation 15 uM] | ||||
yes [Activation 2 uM] | ||||
yes [Activation 3.2 uM] | ||||
yes [Activation 3.9 uM] | ||||
yes [Activation 6.3 uM] | ||||
yes [Activation 7.6 uM] | ||||
yes [Activation 7.9 uM] | ||||
yes [IC50 7.7 uM] | ||||
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/23611293/ |
Sample Use Guides
Clean the affected area and apply a small amount of this product on the
area 1 to 3 times daily. May be covered with a sterile bandage.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18242063
Gentian violet showed the most potent activity against all Candida isolates tested (MIC range, MIC for 50% of the organisms (MIC(50)) and MIC for 90% of the organisms (MIC(90)) of 0.03-0.25 ug/mL, 0.06 ug/mL and 0.1 2 ug/mL, respectively).
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
D01AE02
Created by
admin on Sat Dec 16 01:28:31 GMT 2023 , Edited by admin on Sat Dec 16 01:28:31 GMT 2023
|
||
|
WHO-VATC |
QG01AX09
Created by
admin on Sat Dec 16 01:28:31 GMT 2023 , Edited by admin on Sat Dec 16 01:28:31 GMT 2023
|
||
|
WHO-ATC |
G01AX09
Created by
admin on Sat Dec 16 01:28:31 GMT 2023 , Edited by admin on Sat Dec 16 01:28:31 GMT 2023
|
||
|
CFR |
21 CFR 589.1000
Created by
admin on Sat Dec 16 01:28:31 GMT 2023 , Edited by admin on Sat Dec 16 01:28:31 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1546369
Created by
admin on Sat Dec 16 01:28:31 GMT 2023 , Edited by admin on Sat Dec 16 01:28:31 GMT 2023
|
PRIMARY | RxNorm | ||
|
CHEMBL592105
Created by
admin on Sat Dec 16 01:28:31 GMT 2023 , Edited by admin on Sat Dec 16 01:28:31 GMT 2023
|
PRIMARY | |||
|
77181
Created by
admin on Sat Dec 16 01:28:31 GMT 2023 , Edited by admin on Sat Dec 16 01:28:31 GMT 2023
|
PRIMARY | |||
|
DTXSID10873000
Created by
admin on Sat Dec 16 01:28:31 GMT 2023 , Edited by admin on Sat Dec 16 01:28:31 GMT 2023
|
PRIMARY | |||
|
100000085976
Created by
admin on Sat Dec 16 01:28:31 GMT 2023 , Edited by admin on Sat Dec 16 01:28:31 GMT 2023
|
PRIMARY | |||
|
7438-46-2
Created by
admin on Sat Dec 16 01:28:31 GMT 2023 , Edited by admin on Sat Dec 16 01:28:31 GMT 2023
|
PRIMARY | |||
|
4670
Created by
admin on Sat Dec 16 01:28:31 GMT 2023 , Edited by admin on Sat Dec 16 01:28:31 GMT 2023
|
PRIMARY | |||
|
3468
Created by
admin on Sat Dec 16 01:28:31 GMT 2023 , Edited by admin on Sat Dec 16 01:28:31 GMT 2023
|
PRIMARY | |||
|
3GVJ31T6YY
Created by
admin on Sat Dec 16 01:28:31 GMT 2023 , Edited by admin on Sat Dec 16 01:28:31 GMT 2023
|
PRIMARY | |||
|
DB00406
Created by
admin on Sat Dec 16 01:28:31 GMT 2023 , Edited by admin on Sat Dec 16 01:28:31 GMT 2023
|
PRIMARY | |||
|
SUB03258MIG
Created by
admin on Sat Dec 16 01:28:31 GMT 2023 , Edited by admin on Sat Dec 16 01:28:31 GMT 2023
|
PRIMARY | |||
|
3GVJ31T6YY
Created by
admin on Sat Dec 16 01:28:31 GMT 2023 , Edited by admin on Sat Dec 16 01:28:31 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
SALT/SOLVATE (PARENT)